This study is testing a new combination of two anti-cancer drugs, YL201 and atezolizumab, for people with advanced solid tumors, specifically extensive-stage small cell lung cancer (ES-SCLC). The main goal is to see how safe and tolerable this combination is, especially looking at any dose-limiting toxicities (side effects that are too severe). Researchers will also track other side effects over a longer period. You might be able to join if you are 18 or older, have ES-SCLC that hasn't been treated with systemic anti-cancer therapy before, and meet certain health requirements. The study is looking for about 118 participants.

Study design

This is a Phase Ib/II, multicenter, open-label study. It involves two parts: a dose escalation to find the safest dose, followed by dose optimization and expansion stages. Participants will be randomized in one part of the study.

What's involved

YL201 and atezolizumab will be given intravenously (into a vein) on Day 1 of each 21-day cycle. The study treatment continues until disease progression or death.

Compensation

Not stated in the trial record.

Follow-up

Adverse events will be monitored from the first dose of study treatment up to disease progression or death from any cause, for up to approximately 6 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.